Evidence map›Paper›PMID 35668948›Full record

ArticleFrontiers in pharmacology2022

Metabolomic Profiling for Histologically Fibrotic Stage in Chronic Drug-Induced Liver Injury.

Xian He, Ming-Xi Zhou, Cheng Cheng, Shan-Shan Li, Yuan Gao, Zhi-Tao Ma, Xin-Hua Song, Zhao-Fang Bai, Zheng-Sheng Zou, Xiao-He Xiao and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Xian HeSchool of Pharmacy and Chemistry, Dali University, Dali, China.
Ming-Xi ZhouSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Cheng ChengSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Shan-Shan LiSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Yuan GaoSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Zhi-Tao MaSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Xin-Hua SongSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Zhao-Fang BaiDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Zheng-Sheng ZouDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiao-He XiaoDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Jia-Bo WangSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Ya-Wen LuSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Capital Medical University · CNChinese PLA General Hospital · CNShanxi University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkersdrug-induced liver diseasefingerprintliver fibrosismetabolomics

Identifiers

PMID35668948
PMCPMC9163384
OpenAlexW4280635615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.